News|Articles|November 18, 2026

FDA Accepts sNDA for Selinexor/Ruxolitinib in Myelofibrosis

Fact checked by: Russ Conroy

The FDA has assigned a target action date of June 28, 2027, for selinexor plus ruxolitinib as a therapeutic regimen for patients with myelofibrosis.

The FDA has accepted the supplemental new drug application (sNDA) for selinexor (Xpovio) in combination with ruxolitinib (Jakafi) for the treatment of patients with myelofibrosis, Karyopharm Therapeutics announced.¹

The agency set a Prescription Drug User Fee Act (PDUFA) target action date of June 28, 2027. If approved, selinexor plus ruxolitinib would be the first approved combination therapy for patients with myelofibrosis.

What did the FDA action entail?

The FDA’s acceptance of the sNDA advances selinexor, a first-in-class oral exportin 1 (XPO1) inhibitor, toward a potential expansion into myelofibrosis, a setting in which JAK inhibitors are currently the only approved class of therapy. The application is based primarily on results from the phase 3 SENTRY trial (NCT04562389) and was previously submitted under the accelerated approval pathway. The company plans to use long-term overall survival (OS) data from SENTRY to verify clinical benefit.

What supports the application?

The sNDA is supported primarily by data from the phase 3 SENTRY trial, which evaluated once-weekly selinexor at 60 mg in combination with ruxolitinib compared with placebo plus ruxolitinib in 353 patients with JAK inhibitor–naive myelofibrosis and platelet counts greater than 100 × 10⁹/L. Patients were randomly assigned 2:1 to the selinexor or placebo arm. The coprimary end points were a spleen volume reduction of 35% or greater (SVR35) at week 24 and the average change in absolute total symptom score over 24 weeks relative to baseline.

Results from SENTRY, which showed that selinexor plus ruxolitinib significantly improved spleen responses vs ruxolitinib alone with a manageable safety profile, were presented at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting and simultaneously published in the Journal of Clinical Oncology.2,3 After 24 weeks of treatment, SVR35 was observed in 49.8% (n = 117/235) of patients receiving selinexor/ruxolitinib and 28.0% (n = 33/118) of those receiving placebo/ruxolitinib (odds ratio, 2.58; 95% CI, 1.60-4.17; P <.0001). The treatment effect observed with the selinexor combination was consistent across prespecified patient subgroups.

Adverse effects (AEs) of any grade occurred in 99.1% (n = 232/234) of patients in the selinexor arm and 97.4% (n = 113/116) of those in the placebo arm; 70.1% (n = 164/234) and 50.0% (n = 58/116) of patients in each respective arm experienced grade 3 or higher AEs. The most common AEs in each respective arm included thrombocytopenia (59.4% vs 43.1%), anemia (57.3% vs 57.8%), and nausea (57.3% vs 17.2%).

“FDA acceptance of our sNDA is a significant milestone in the development of selinexor for patients with myelofibrosis and marks an important step toward expanding selinexor’s impact and reach,” said Richard Paulson, president and chief executive officer of Karyopharm, in a news release.1

What is selinexor, and what comes next?

Selinexor functions by selectively binding to and inhibiting the nuclear export protein XPO1 and is approved in the US in combination regimens for patients with multiple myeloma. The FDA is expected to make a decision on the sNDA by the June 28, 2027, target action date, and Karyopharm stated that it is preparing for a potential launch of the combination.

Developers originally submitted the sNDA for selinexor plus ruxolitinib as a treatment for myelofibrosis in August 2026.4

“[Patients with] myelofibrosis patients continue to [experience] a significant unmet need, with JAK inhibitors as the only approved class of therapy. Selinexor offers a differentiated mechanism of action and, if approved, selinexor plus ruxolitinib could become the first approved combination therapy for patients with myelofibrosis,” Reshma Rangwala, MD, PhD, chief medical officer and head of research of Karyopharm, concluded.1

References

  1. Karyopharm announces FDA acceptance of supplemental new drug application for Xpovio (selinexor) plus ruxolitinib for the treatment of patients with myelofibrosis. News release. Karyopharm Therapeutics Inc. November 17, 2026. Accessed November 18, 2026. https://tinyurl.com/mxhh9r3p
  2. Mascarenhas J, Ali H, Al-Ali HK, et al. Selinexor plus ruxolitinib in JAK inhibitor–naïve myelofibrosis: phase 3 SENTRY trial. J Clin Oncol. 2026;44(suppl 17):LBA6500. doi:10.1200/JCO.2026.44.17_suppl.LBA6500
  3. Bose J, Ali H, Al-Ali HK, et al. Selinexor plus ruxolitinib in Janus kinase inhibitor–naïve myelofibrosis: phase III SENTRY trial. J Clin Oncol. 2026;44(22):2098-2109. doi:10.1200/JCO-26-01080
  4. Karyopharm submits supplemental new drug application to the FDA for Xpovio (selinexor) plus ruxolitinib for patients with myelofibrosis. News release. Karyopharm Therapeutics Inc. August 31, 2026. Accessed November 18, 2026. https://tinyurl.com/ynpfv7pa

Related to this article